謝 燿宇

Medicine & Life Sciences

1. Colorectal Neoplasms 100%
2. Taiwan 74%
3. Adenocarcinoma 64%
4. Azacitidine 63%
5. Imatinib Mesylate 62%
6. Decitabine 61%
7. Cetuximab 60%
8. Oxaliplatin 59%
9. Bone Neoplasms 58%
10. Genomics 57%
11. Computational Biology 56%
12. Neoplasm Metastasis 55%
13. Drug Therapy 53%
14. Squamous Cell Carcinoma of Head and Neck 53%
15. GW8510 53%
16. UNC1999 51%
17. Polypharmacology 51%
18. Oncogenes 51%
19. GSK343 50%
20. Drug Discovery 49%
21. Survival 47%
22. Fedratinib 46%
23. ErbB Receptors 45%
24. Computer Simulation 45%
25. Protein-Tyrosine Kinases 43%
26. Cisplatin 43%
27. ribonucleotide reductase M2 42%
28. Neoplasms 42%
29. 3-ingenyl angelate 41%
30. S100 Calcium-Binding Protein A4 38%
31. Genes 38%
32. Prostatic Neoplasms 37%
33. Immunogenic Cell Death 37%
34. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 37%
35. Enhancer of Zeste Homolog 2 Protein 36%
36. K562 Cells 36%
37. Interferon Regulatory Factor-1 36%
38. Areca 35%
39. Medicine 34%
40. Catfishes 34%
41. Lapatinib 33%
42. Janus Kinase 2 33%
43. liposomal doxorubicin 33%
44. Drug Resistance 33%
45. Janus Kinase Inhibitors 33%
46. Calreticulin 33%
47. Drug Repositioning 32%
48. Irinotecan 32%
49. Histone Deacetylase Inhibitors 32%
50. Synovial Sarcoma 32%